HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin.

AbstractBACKGROUND:
In some patients with Churg-Strauss syndrome (CSS), especially those with myocardial or neural involvement, conventional treatment with corticosteroids with or without cyclophosphamide is not effective.
OBJECTIVE:
To examine the effects of intravenous high-dose immunoglobulin (IVIG) in patients with CSS who showed poor responsiveness to conventional treatment.
METHODS:
We consecutively selected patients with CSS who showed any organ involvement despite corticosteroid treatment with or without cyclophosphamide. The diagnosis was based on the classification criteria of the American College of Rheumatology. IVIG therapy was performed with a dose of 400 mg/kg of immunoglobulin daily for 5 days. Neuropathy was evaluated with the manual muscle strength test and by the skin temperature of affected sites. Cardiac function was examined with ejection fraction by echocardiography and 2 imaging tests of myocardium (iodine 123 metaiodobenzylguanidine and thallium 201).
RESULTS:
The manual muscle strength test results were improved, and the skin temperature of both hands and legs was increased by IVIG therapy. In 5 patients with heart failure, the mean +/- SD ejection fraction of the left ventricle increased from 35.2% +/- 13.9% to 61.0% +/- 10.1% (P < .02). The uptake of iodine 123 metaiodobenzylguanidine of the myocardium increased, indicating that the myocardial viability was improved. The thallium 201 images revealed the presence of perfusion defects, which were improved by IVIG therapy.
CONCLUSIONS:
Patients with CSS who are resistant to corticosteroid treatment with or without cyclophosphamide may be treated effectively with IVIG therapy.
AuthorsNaomi Tsurikisawa, Masami Taniguchi, Hiroshi Saito, Hideo Himeno, Akihiko Ishibashi, Shunsuke Suzuki, Kazuo Akiyama
JournalAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (Ann Allergy Asthma Immunol) Vol. 92 Issue 1 Pg. 80-7 (Jan 2004) ISSN: 1081-1206 [Print] United States
PMID14756469 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Adrenal Cortex Hormones
  • Immunoglobulins, Intravenous
  • Cyclophosphamide
Topics
  • Adrenal Cortex Hormones (therapeutic use)
  • Adult
  • Aged
  • Churg-Strauss Syndrome (complications, drug therapy)
  • Cyclophosphamide (therapeutic use)
  • Female
  • Heart Failure (complications, drug therapy)
  • Humans
  • Immunoglobulins, Intravenous (administration & dosage, therapeutic use)
  • Male
  • Middle Aged
  • Peripheral Nervous System Diseases (complications, drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: